Physician profile
Aaron Kern
NPI 1891726725
$2,961.95
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $756 · 2021: $1,090 · 2022: $17.99 · 2023: $22.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $397.81 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $355.24 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $242.64 | 2019-2021 | |
| Pfizer INC. | $228.35 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $221.66 | 2019-2021 | |
| Glaxosmithkline, LLC. | $174.76 | 2019-2021 | |
| Lilly USA, LLC | $125.81 | 2020-2021 | |
| Abbvie INC. | $114.20 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $105.47 | 2019-2021 | |
| Amgen INC. | $101.91 | 2019-2021 | |
| Allergan, INC. | $94.61 | 2019-2020 | |
| Eisai INC. | $80.47 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $78.26 | 2019-2021 | |
| Novo Nordisk INC | $66.80 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.54 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $66.03 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $64.56 | 2019 | |
| Amarin Pharma, INC. | $64.01 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $63.34 | 2021 | |
| Esperion Therapeutics, INC. | $46.40 | 2021 | |
| Mallinckrodt Hospital Products INC. | $36.81 | 2020 | |
| Radius Health, INC. | $36.77 | 2019-2021 | |
| Nevro Corp. | $22.95 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $22.78 | 2019 | |
| Sanofi Pasteur INC. | $18.05 | 2019 | |
| Linus Health, INC. | $17.99 | 2022 | |
| Pharming Healthcare, INC. | $17.32 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.65 | 2020 | |
| Medtronic Vascular, INC. | $14.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Kern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.